Last checked at 12 Apr 2017 12:41
The following amendments have been made to the ' Exercise of share options' announcement released on 29 March 2017 at 15.30 under RNS No 9236A.
The date of admission of the New Ordinary Shares is 20 April 2017.
All other details remain unchanged.
The full amended text is shown below.
12 April 2017
IXICO plc
("IXICO" or the "Company")
Exercise of share options
IXICO, the brain health company, announces that Dr Janet Munro and Mr Ken Tubman have exercised options granted to them by Optimal Medicine Limited. In accordance with the terms of the Share Purchase Agreement between the Company and Optimal Medicine Limited on 18 November 2015 ('the Agreement') the new shares issued and allotted in Optimal Medicine Limited are subject to a put and call arrangement resulting in the Company issuing and allotting 55,846 new ordinary shares of 1 pence each in IXICO plc (the "New Ordinary Shares")
Application has been made for the New Ordinary Shares to be admitted to AIM on 20 April 2017. Upon admission of the New Ordinary Shares to AIM, the enlarged issued share capital of the Company will be 27,119,130 ordinary shares.
The Company does not hold any shares in treasury. Consequently, 27,119,130 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
| |||
| |||||
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield | Tel: +44 20 7408 4090 |
| |||
| |||||
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss | Tel: +44 20 3727 1000 |
| |||
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com